Navigation Links
Halozyme to Host Fourth Quarter and 2011 Year-End Financial Results Conference Call

SAN DIEGO, March 1, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the fourth quarter and full year 2011 on Friday, March 9, 2012 at 8:00 a.m. ET/5:00 a.m. PT. Greg I. Frost, President and Chief Executive Officer, will lead the call. On the same date pre-market, Halozyme will release financial results for the fourth quarter and year-ended December 31, 2011.


The call will be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made available following the close of the call. To access the webcast, please log on to approximately fifteen minutes prior to the call to register, download and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (877) 407-8037 (domestic callers) or (201) 689-8037 (international callers). A telephone replay will be available shortly after the call by dialing (877) 660-6853 (domestic callers) or (201) 612-7415 (international callers) using account number 367 and replay ID number 390311.

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, that increase the absorption and dispersion of biologics. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need. The Company markets HYLENEX® recombinant (hyaluronidase human injection) and has partnerships with Roche, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at

Media/Investor Contact:
Anne Erickson
Executive Director
Halozyme Therapeutics

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Halozyme Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference
2. Halozyme Therapeutics Reports Third Quarter 2011 Financial Results
3. Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
4. Halozyme Begins Clinical Trial with HTI-501 in Women with Edematous Fibrosclerotic Panniculopathy
5. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
6. Halozyme Therapeutics to Present Data on its Ultrafast Insulin Programs at the Upcoming American Diabetes Association 71st Scientific Sessions
7. Halozyme Therapeutics to Present at the Jefferies 2011 Global Healthcare Conference on June 9
8. Halozyme Therapeutics Reports First Quarter 2011 Financial Results
9. Halozymes Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
10. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
11. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
Post Your Comments:
(Date:11/30/2015)... ... 2015 , ... Global Stem Cells Group announced the opening of a new core ... and Iquique in northern Chile. The facilities are part of GSCG’s expansion efforts in Latin ... techniques in stem cell medicine to patients from around the world. , The clinics will ...
(Date:11/30/2015)... , December 1, 2015 Partnership includes an ... for the u niversity , ... support treatment s cale - up ... (ARVs)   Africa , where licensees based anywhere in the ... on SDN technology. --> Africa , where licensees based anywhere ...
(Date:11/30/2015)... /PRNewswire/ - Zenith Epigenetics Corp. ("Zenith" or the "Company") today ... to its Board of Directors to replace Dr. ... wealth of experience as co-founder of Resverlogix, with expertise in ... --> --> Dr. Wong remarked, "I am ... Zenith,s long standing expertise in epigenetics and the advanced stage ...
(Date:11/30/2015)...  Champions Oncology, Inc. (CSBR), engaged in the development ... development and use of oncology drugs, today announced that ... presenting at the LD MICRO Investor Conference on Wednesday, ... The conference, held at the Luxe Sunset Bel Air ... will feature 200 small/micro-cap companies and is expected to ...
Breaking Biology Technology:
(Date:11/4/2015)... November 4, 2015 --> ... report published by Transparency Market Research "Home Security Solutions Market ... Forecast 2015 - 2022", the global home security solutions market is ... by 2022. The market is estimated to expand at ... 2015 to 2022. Rising security needs among customers at ...
(Date:10/29/2015)... , Oct. 29, 2015   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... Tech Association (MHTA) as one of only three finalists ... "Software – Small and Growing" category. The Tekne Awards honor ... have shown superior technology innovation and leadership. ...
(Date:10/29/2015)... 2015 Daon, a global leader in mobile ... a new version of its IdentityX Platform , ... America have already installed IdentityX v4.0 and ... FIDO UAF certified server component as an ... FIDO features. These customers include some of the largest ...
Breaking Biology News(10 mins):